MHRA paediatric investigation plan
Teplizumab (Teplizumab)
MHRA paediatric investigation plan MHRA-100139-PIP01-21 · Agreement
Key facts
| PIP number | MHRA-100139-PIP01-21 |
|---|---|
| Active substances | Teplizumab |
| Therapeutic areas | Endocrinology-Gynaecology-Fertility-metabolism |
| Conditions | Prevention or delay of (clinical) type 1 diabetes mellitus |
| Decision | P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) |
| Published | Oct 9, 2024 |
| MHRA record | cms.mhra.gov.uk |
About MHRA paediatric investigation plans
A paediatric investigation plan sets out the studies a company must run in children to support authorisation of a medicine in the UK, or records a waiver or deferral.
Source: UK Medicines and Healthcare products Regulatory Agency (MHRA). Contains public sector information licensed under the Open Government Licence v3.0 · Source date: